Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Murai, T. Articles by Barthel, H. Search for Related Content PubMed Citation Articles by Murai, T. Articles by Barthel, H. Parkinson's Disease

In Vivo Evidence for Differential Association of Striatal Dopamine and Midbrain Serotonin Systems With Neuropsychiatric Symptoms in Parkinson's Disease

Received November 16, 1999; revised June 6, 2000; accepted June 13, 2000. From the Max Planck Institute of Cognitive Neuroscience, Leipzig; Departments of Psychiatry, Cognitive Neurology, and Nuclear Medicine, University of Leipzig; and Neurological Clinic Martha-Maria, Halle/Saale, Germany. Address correspondence to Dr. Murai, Department of Psychiatry, Faculty of Medicine, Kyoto University, Shogoin-Kawaharacho 54, 606-8507 Kyoto, Japan. E-mail:murai{at}kuhp kyoto-u.ac.jp.

Parkinson's disease affects various neurotransmitter systems. Using SPECT, the authors measured [¹²³I]ß-CIT binding ratios of the caudate, putamen, medial thalamus, and dorsal midbrain over cerebellum in 16 patients with Parkinson's disease, and examined correlations with clinical ratings. Whereas striatal binding ratios (reflecting regional dopamine transporter densities) were associated with motor symptoms, dorsal midbrain binding ratios (reflecting regional serotonin transporter densities) were significantly correlated with the mentation, behavior, and mood subscale of the Unified Parkinson's Disease Rating Scale. These findings indicate that degeneration of the nigrostriatal dopaminergic neurons and a dysfunctional serotonergic raphe system contribute differentially to motor deficits and neuropsychiatric symptoms in Parkinson's disease.

Key Words: Dopamine • Serotonin • Parkinson's Disease

This article has been cited by other articles:

				T. N. Taylor, W. M. Caudle, K. R. Shepherd, A. Noorian, C. R. Jackson, P. M. Iuvone, D. Weinshenker, J. G. Greene, and G. W. Miller Nonmotor Symptoms of Parkinson's Disease Revealed in an Animal Model with Reduced Monoamine Storage Capacity J. Neurosci., June 24, 2009; 29(25): 8103 - 8113. [Abstract] [Full Text] [PDF]

				H. Barthel, S. Hesse, and O. Sabri 123I-{beta}-CIT SPECT for Imaging Serotonin Transporters in Parkinson's Disease J. Nucl. Med., May 1, 2004; 45(5): 923 - 924. [Full Text] [PDF]

				A.E. Lang, G. Kleiner-Fisman, J.A. Saint-Cyr, J. Miyasaki, A. Lozano, J.L. Houeto, V. Mesnage, M.L. Welter, L. Mallet, Y. Agid, et al. Subthalamic DBS replaces levodopa in Parkinson's disease: Two-year follow-up Neurology, January 14, 2003; 60(1): 154 - 155. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2001 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us